commonly seen in young patients (32%-77% of patients were younger than 20 years of age in a large series [4] ) and is more commonly described in individuals of Asian ethnicity. Aneurysm formation occurs in 15%-30% of patients with TA, particularly children [4] . The cause of TA is unknown, although an autoimmune process has been postulated. There were early reports of Mycobacterium tuberculosis infection in association with TA in areas where tuberculosis is highly endemic, but a direct causal relationship has not been demonstrated [5] . No cases of concurrent TA and HIV infection were found in a review of the world literature despite these diseases having similar geographic distributions and age incidences in Asia. No direct causal relationship could be demonstrated between HIV infection, suspected tuberculous infection, and large vessel arteritis in this case, and the patient's ethnicity and geographic location may make this a chance occurrence. However, the possible autoimmune nature of TA and the observed frequency of autoimmune phenomena in HIV infection should make this combination more likely, especially in children.
Stavudine-Induced Macrocytosis During Therapy for Human Immunodeficiency Virus Infection
Nucleoside analogue reverse transcriptase inhibitors are important components of most treatment regimens for HIV infection. Three of these agents (zidovudine, zalcitabine, and didanosine) have been known to cause leukopenia, anemia, and/or thrombocytopenia. Zidovudine has been associated most frequently with dose-related bone marrow toxicity manifested as macrocytic anemia. Stavudine and lamivudine have not been reported to cause hematologic toxicity at currently recommended doses [1, 2] .
We noted that as patients' treatments were switched from zidovudine-to stavudine-containing regimens, there was minimal or no decrease in macrocytosis, while there was a rapid return to baseline mean corpuscular volumes (MCVs) in patients receiving non-stavudine-containing regimens. Zidovudinenaive patients who began stavudine treatment were noted to have increases in MCVs similar to those in patients taking zidovudine therapy. Some of the MCVs were remarkable enough (Ͼ110 fL) to prompt investigation of vitamin B 12 and folate levels (which were normal in all seven patients tested). Although phase 1 studies revealed that anemia and macrocytosis occurred in patients receiving dosages higher than those currently used, stavudine at currently recommended dosages has not been reported in the literature (or the package insert) to cause hematologic abnormalities [3] .
We retrospectively reviewed the charts of 122 patients whose treatment regimens included stavudine. Thirty-one patients (10, stavudine therapy for Ͻ3 months; 10, poorly documented or changing treatment regimens; 7, documented noncompliance; and 4, lost to follow-up) were excluded from the study. Of the 91 remaining patients, none had a known history of alcohol abuse or malabsorption syndromes.
The results of the chart review are shown in figure 1 . Macrocytosis was observed in 89% of patients as defined by an MCV of Ͼ95.0 fL and in 73% as defined by an MCV of Ͼ100.0 fL. The mean MCV at initiation of stavudine treatment was 96.3 fL (range, 78.9 -118.8 fL). The mean MCV at least 3 months after initiation of stavudine treatment was 104.6 fL (range, 79.0 -122.1 fL). The mean increase in MCV was 9.3 fL (range, Ϫ10.3 to 29.3 fL; P Ͻ .05).
Fifty-three percent of patients were zidovudine naive before initiation of stavudine treatment. These patients had a mean MCV of 89.5 fL (range, 78.9 -99.5 fL) at initiation of therapy and a mean increase in MCV of 13.9 fL (range, 0.1-29.4 fL; P Ͻ .05) at least 3 months after initiation of stavudine treatment. Forty-seven percent of patients had previously received zidovudine treatment before stavudine therapy was initiated. These patients had a mean MCV of 103.9 fL (range, 81.3-118.8 fL) at initiation of therapy and a statistically insignificant mean increase in MCV of 2.2 fL (range, 10.3-20.2 fL; P ϭ .11) at least 3 months after stavudine was substituted.
Stavudine was used in conjunction with lamivudine therapy for 79 (87%) of the patients. Of 12 patients taking stavudine without lamivudine therapy, 10 (83%) had an MCV of Ͼ95.0 fL and five (42%) had an MCV of Ͼ100.0 fL. Lamivudine monotherapy (as used in phase 2/3 trials) is uncommonly associated with macrocytosis (only at doses at least twice as high as those currently administered).
Macrocytosis induced by zidovudine is often associated with anemia. Anemia has not typically been associated with stavudine therapy. In our patients, there was actually a small, but statistically significant, increase in hemoglobin levels with stavudine therapy. This increase was accentuated in patients whose treatment was switched from zidovudine who had an initial hemoglobin concentration of Ͻ12 g/dL. The mean baseline hemoglobin level for all 91 patients was 13.4 g/dL (range, 8.4 -17.2 g/dL), and the mean hemoglobin level after at least 3 months of stavudine treatment was 14.2 g/dL (range, 10.1-17.1 g/dL; P Ͻ .05). For those patients for whom stavudine was substituted for zidovudine treatment, the mean baseline hemoglobin level was 12.9 g/dL (range, 5.5-17.2 g/dL), and the mean hemoglobin concentration after at least 3 months of therapy was 14.1 g/dL (range, 11.7-17.1 g/dL; P Ͻ .05).
As treatment of HIV infection has evolved, ever more complex regimens with five or more drugs in combination are being used. There have been limited clinical trials of many of the drugs before widespread use, and toxicities are discovered only after significant use outside of these trials. Unexplained macrocytosis in an HIVinfected patient receiving combination therapy may lead to an extensive workup for bone marrow or gastrointestinal disease. Alternately, macrocytosis may be attributed to a new agent as a yet undescribed toxic effect. Fortunately, macrocytosis associated with stavudine, at the currently recommended doses, is not associated with anemia.
We conclude that the finding of isolated macrocytosis, without anemia, in a patient being treated with stavudine may be due primarily to stavudine itself and may not warrant further evaluation.
Refractory Craniofacial Actinomycetoma Due to Streptomyces somaliensis That Required Salvage Therapy with Amikacin and Imipenem
Mycetoma is a chronic skin infection that can be caused by aerobic actinomycetes (actinomycetoma) and fungi (eumycetoma). Most mycetomas involve the legs and feet, and only few cases of craniofacial mycetoma have been reported. Mycetoma results from inoculation of the microorganism through a minor injury caused by a thorn or infection of an existing lesion. We report a case of mycetoma of the face and skull due to Streptomyces somaliensis resistant to co-trimoxazole clinically and in vitro.
A 27-year-old Mauritanian female had a 10-year history of craniofacial mycetoma. Initially, specific therapy with isoniazid, rifampin, and pyrazinamide was started for presumptive cutaneous tuberculosis. The skin lesions had evolved into firm nodules and abscesses. In 1995, biopsy was carried out, and histological examination (performed by Dr. M. Huerre, Institut Pasteur, Paris) confirmed that the granulomatous lesions were due to S. somaliensis. After 8 months of treatment with co-trimoxazole and dapsone, there was no improvement; treatment was switched to streptomycin and rifampin for 5 months.
At presentation to our department in May 1997, she had severe headaches and trismus, the latter caused by bacterial infiltration of the right temporal muscles of mastication and the mandibular joint. Cranial radiographs showed multiple osteolytic bone lesions (figure 1, A) . CT and MRI confirmed the involvement of subcutaneous tissue, fascia, muscle, bone, and the underlying extradural space ( figure 1, B-D) . The exudate from an abscess contained hard, rounded, chamois-yellow granules 2 mm in diameter. Considering the life-threatening nature of the infection, presumptive combination therapy with imipenem (500 mg t.i.d.) and amikacin (15 mg/[kg ⅐ d] once daily) was started.
After 1 month, cultures (performed by P. Boiron, Institut Pasteur, Paris, according to a technique described elsewhere [1] ) yielded S. somaliensis on Löwenstein-Jensen medium. The isolate was then sent to the Division of Mycotic Diseases (Dr. M. M. McNeil), Centers for Disease Control and Prevention, for susceptibility testing [2] ; it was found to be resistant in vitro to cotrimoxazole but susceptible to amikacin, ampicillin, cefotaxime, erythromycin, minocycline, doxycycline, imipenem, and ciprofloxacin. The patient was discharged after 3 months of therapy. Because amikacin was provided free of charge (Bristol-MyersSquibb, Paris) for an additional 3 months, a new treatment course with amikacin and ampicillin was started in Mauritania. At a
